An observational study demonstrating the adherence and ease of use of the injector device, RebiSmart®-Reference-Cited by-同舟云学术

An observational study demonstrating the adherence and ease of use of the injector device, RebiSmart®

Published:2020-04-21 Issue:5 Volume:17 Page:719-724
ISSN:1742-5247
Container-title:Expert Opinion on Drug Delivery
language:en
Short-container-title:Expert Opinion on Drug Delivery

Author:

Vališ Martin¹,Šarláková Jana¹,Halúsková Simona¹,Klímová Blanka¹,Potužník Pavel²,Peterka Marek²,Kuča Kamil³,Štourač Pavel⁴,Mareš Jan⁵,Pavelek Zbyšek¹^ORCID

Affiliation:

1. Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic

2. Department of Neurology, Faculty of Medicine and University Hospital Plzeň, Charles University in Prague, Plzeň, Czech Republic

3. Faculty of Science, Department of Chemistry, University of Hradec Králové, Hradec Králové, Czech Republic

4. Department of Neurology, University Hospital and Masaryk University, Brno, Czech Republic

5. Department of Neurology, Faculty of Medicine, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic

Funder

Ministry of Health of the Czech Republic

Charles University in Prague, Czech Republic

Publisher

Informa UK Limited

Subject

Pharmaceutical Science

Link

https://www.tandfonline.com/doi/pdf/10.1080/17425247.2020.1742694

Reference22 articles.

1. Natural history of multiple sclerosis

2. The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration

3. Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15

4. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. REBISTART: Adherence of Patients with Multiple Sclerosis to Treatment with Subcutaneous Interferon Beta in the Context of a Patient Support Program;Neurology and Therapy;2024-03-26

2. Preferences and Perspectives of Specialist Multiple Sclerosis Nurses and Patients with Multiple Sclerosis Regarding the New RebiSmart® 3.0 Autoinjector versus Other Assistive Devices;Medical Devices: Evidence and Research;2024-02

3. Adherence to subcutaneous interferon beta-1a treatment among patients with relapsing multiple sclerosis: the MAIN-MS study;Frontiers in Neurology;2023-11-28

4. Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation;Expert Review of Clinical Immunology;2023-09-11

5. Preferences and perspectives of MS nurses and patients with multiple sclerosis regarding the new RebiSmart® 3.0 autoinjector versus other assistive devices;2023-08-17